Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Johnson & Johnson (JNJ)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN – Research Report) and Johnson & Johnson (JNJ – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Legend Biotech (LEGN)
In a report released yesterday, Yaron Werber from TD Cowen downgraded Legend Biotech to Hold, with a price target of $21.00. The company’s shares closed last Wednesday at $20.76.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $63.20.
See today’s best-performing stocks on TipRanks >>
Johnson & Johnson (JNJ)
TD Cowen analyst Josh Jennings reiterated a Buy rating on Johnson & Johnson yesterday and set a price target of $250.00. The company’s shares closed last Wednesday at $218.01.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $224.91, implying a 6.6% upside from current levels. In a report issued on January 7, RBC Capital also maintained a Buy rating on the stock with a $240.00 price target.
